National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA.
Am J Chin Med. 2011;39(4):779-88. doi: 10.1142/S0192415X11009184.
Ginseng is one of the most popular herbal supplements on the US market. Numerous reports of adverse effects from products containing ginseng have been filed with the US Food and Drug Administration (FDA) and the literature documents a "ginseng abuse syndrome" among regular users. However, the chronic toxic effects of ginseng are not well characterized. Because of its significant human exposure and the fact that little information on its toxicity is available, Panax ginseng was nominated by the US National Institutes of Health (NIH) to the US National Toxicology Program (NTP) to assess its carcinogenic potential. In this paper, we reported the results of NTP chronic toxicity and tumorigenicity bioassay. It shows that, under these experimental conditions, Panax ginseng is not toxic or tumorigenic.
人参是美国市场上最受欢迎的草药补充剂之一。美国食品和药物管理局（FDA）收到了大量关于含人参产品不良反应的报告，文献也记录了经常使用者中的“人参滥用综合征”。然而，人参的慢性毒性作用尚未得到很好的描述。由于其对人类的大量暴露，以及有关其毒性的信息很少，美国国立卫生研究院（NIH）提名人参作为美国国家毒理学计划（NTP）的评估对象，以评估其致癌潜力。在本文中，我们报告了 NTP 慢性毒性和肿瘤发生生物测定的结果。结果表明，在这些实验条件下，人参没有毒性或致癌性。
